GNTbm-38, a Novel Epigenetic Modulator, Performs Immune Activation and Reprogramming of the Tumor Microenvironment.
The efficacy of immunotherapy depends on the composition of immune cells, including cytotoxic T cells (CTLs), etc., in the tumor microenvironment (TME). However, a significant proportion of patients with pre-existing immunity fail to respond to current immunotherapy, indicating the search of drugs/combinations with the...